Modern possibilities for the correction of menopausal symptoms in patients with breast cancer, depending on the molecular biological characteristics of the tumor (literature review)

Cover Page

Cite item

Full Text

Abstract

Breast cancer (BC) ranks first in cancer incidence among women. For successful treatment of BC, depending on the molecular type and stage of the disease, chemotherapy is used, the side effects of which are manifested by menopausal symptoms, sexual dysfunction, and depressive states. However, not all patients after BC receive appropriate therapy for menopausal symptoms, what significantly worsens their quality of life. One of the symptoms that brings the most severe discomfort is the vasomotor symptom, a form of temperature dysfunction with peripheral vasodilation and increased cutaneous blood flow that results in increased heat loss. There are several types of drugs that are used to prevent menopausal symptoms in patients taking endocrine chemotherapy, many of which are in the experimental phase of development. In this review, we will try to identify proven effective and safe methods for correcting menopausal symptoms in women who underwent chemotherapy and endocrine therapy for BC.

About the authors

I. V. Vysotskaya

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Author for correspondence.
Email: vysotskaya.irinavic63@gmail.com
ORCID iD: 0000-0001-8814-636X

Irina Viktorovna Vysotskaya

Build. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

E. A. Kim

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0003-4893-8770

Build. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

M. V. Geletko

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0001-9432-1064

Build. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

F. E. Misrikhanova

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0009-0005-6328-9109

Build. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

V. Yu. Kirsanov

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

ORCID iD: 0000-0003-0040-3136

Build. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

References

  1. Mazor M., Lee K., Dhruva A. et al. Menopausal-related symptoms in women one year after breast cancer surgery. J Pain Symptom Manage 2018;55(4):1138–51.e1. doi: 10.1016/j.jpainsymman.2017.11.030
  2. Peate M., Saunders C., Cohen P. et al. Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors. Breast Cancer Res Treat 2021;187:427–35. doi: 10.1007/s10549-021-06117-7
  3. Rozenberg S., Di Pietrantonio V., Vandromme J. Hormone therapy during menopause and the risk of breast cancer. Best Pract Clin Endocrinol 2021;35(6):101577. doi: 10.1016/j.beem.2021.101577
  4. Wang S.M., Pfeiffer R.M., Gierach G.L. et al. Use of postmenopausal hormone therapies and risk of histologyand hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort. Breast Cancer Res 2020;22(129). doi: 10.1186/s13058-020-01365-9
  5. Marchetti C., De Felice F., Boccia S. et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit Rev Oncol Hematol 2018;132:111–5. doi: 10.1016/j.critrevonc.2018.09.018
  6. Rozenberg S., Di Pietrantonio V., Vandromme J., Gilles C. Menopausal hormone therapy and breast cancer risk. Best Pract Res Clin Endocrinol Metab 2021;35(6):101577. doi: 10.1016/j.beem.2021.101577
  7. Poorolajal J., Heidarimoghis F., Karami M. et al. Factors for the primary prevention of breast cancer: A meta-analysis of prospective cohort studies. J Res Health Sci 2021;21(3):e00520. doi: 10.34172/jrhs.2021.57
  8. Garcia-Recio S., Gascón P. Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int 2015;2015:495704. doi: 10.1155/2015/495704
  9. Page N.M. New challenges in the study of the mammalian tachykinins. Peptides 2005;26(8):1356–68. doi: 10.1016/j.peptides.2005.03.030
  10. Rance N.E., Dacks P.A., Mittelman-Smith M.A. et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013;34(3):211–27. doi: 10.1016/j.yfrne.2013.07.003
  11. Rometo A.M., Krajewski S.J., Voytko M.L., Rance N.E. Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys. J Clin Endocrinol Metab 2007;92(7):2744–50. doi: 10.1210/jc.2007-0553
  12. Rance N.E., Young W.S. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology 1991;128(5):2239–47. doi: 10.1210/endo-128-5-2239
  13. Trower M., Anderson R.A., Ballantyne E. et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause 2020;27(5):498–505. doi: 10.1097/GME.0000000000001500
  14. Simon J., Anderson R.A., Ballantyne E. et al. OR11-03 NT-814, a non-hormonal dual neurokinin 1,3 receptor antagonist markedly improves vasomotor symptoms in post-menopausal women; results of a randomised, double-blind, placebo-controlled, dose-finding study (SWITCH-1). J Endocr Soc 2020;4(Suppl 1):OR11-03. doi: 10.1210/jendso/bvaa046.2071
  15. Bansal R., Aggarwal N. Menopausal hot flashes: A concise review. J Midlife Health 2019;10(1):6–13. doi: 10.4103/jmh.JMH_7_19
  16. Walling A.D. Gabapentin reduces hot flashes in breast cancer survivors. Am Fam Physician 2006;73(6):1100–2.
  17. Raus K., Brucker C., Gorkow C., Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 2006;13(4):678–91. doi: 10.1097/01.gme.0000196813.34247.e2
  18. Gordeeva G.D. Efficacy of phyto-pharmaceutical climadinon in women with menopausal syndrome of various genesis. Reproduktivnoe zdorovye zhenshchiny = Women’s Reproductive Health 2003;1(13):84–90. (In Russ.)
  19. Wuttke W., Raus K., Gorkow C. Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placeboand conjugated estrogens-controlled study. Maturitas 2006;55S:S83–S91. doi: 10.1016/j.maturitas.2006.06.020
  20. Trant A.A., Chagpar A., Wei W. et al. The effect of Black cohosh on Ki67 expression and tumor volume: A pilot study of ductal carcinoma in situ patients. Integr Cancer Ther 2022;21:15347354221137290. doi: 10.1177/15347354221137290
  21. Drewe J., Boonen G., Culmsee C. Treat more than heat – New therapeutic implications of Cimicifuga racemosa through AMPK-dependent metabolic effects. Phytomedicine 2022;100:154060. doi: 10.1016/j.phymed.2022.154060
  22. Mann E., Smith M., Hellier J., Hunter M.S. A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): Trial protocol. BMC Cancer 2011;11:44. doi: 10.1186/1471-2407-11-44
  23. Ayers B., Smith M., Hellier J. et al. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): A randomized controlled trial. Menopause 2012;19(7):749–59. doi: 10.1097/gme.0b013e31823fe835
  24. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22(11):1155–72; quiz 1173–4. doi: 10.1097/GME.0000000000000546
  25. Sahni S., Lobo-Romero A., Smith T. Contemporary non-hormonal therapies for the management of vasomotor symptoms associated with menopause: A literature review. TouchREV Endocrinol 2021;17(2):133–7. doi: 10.17925/EE.2021.17.2.133
  26. Rios E.R., Venâncio E.T., Rocha N.F. et al. Melatonin: pharmacological aspects and clinical trends. Int J Neurosci 2010;120(9):583–90. doi: 10.3109/00207454.2010.492921
  27. Ezzati M., Velaei K., Kheirjou R. Melatonin and its mechanism of action in the female reproductive system and related malignancies. Mol Cell Biochem 2021;476(8):3177–90. doi: 10.1007/s11010-021-04151-z
  28. Dodda B.R., Bondi C.D., Hasan M. et al. Co-administering melatonin with an estradiol-progesterone menopausal hormone therapy represses mammary cancer development in a mouse model of HER2-positive breast cancer. Front Oncol 2019;9:525. doi: 10.3389/fonc.2019.00525
  29. Van Barele M., Heemskerk-Gerritsen B.A.M., Louwers Y.V. et al. Estrogens and progestogens in triple negative breast cancer: Do they harm? Cancers (Basel) 2021;13(11):2506. doi: 10.3390/cancers13112506

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.